Chemistry:2CB-2OCD3

From HandWiki

2CB-2OCD3
Clinical data
Other names2C-B-2-OCD3; 2-Trideuteromethoxy-2C-B; 4-Bromo-2-trideuteromethoxy-5-methoxyphenethylamine; 2-(4-Bromo-5-methoxy-2-(methoxy-d3)phenyl)ethan-1-amine
Drug classSerotonin 5-HT2A receptor agonist; Possible serotonergic psychedelic or hallucinogen
ATC code
  • None
Identifiers
PubChem CID
Chemical and physical data
FormulaC10H14BrNO2
Molar mass260.131 g·mol−1
3D model (JSmol)

2CB-2OCD3, also known as 2-trideuteromethoxy-2C-B, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families.[1][2] It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 2 position have been replaced with the deuterium isotopes.[1][2] The drug shows similar serotonin 5-HT2A receptor pharmacodynamics and metabolism as 2C-B in vitro.[1][2] The chemical synthesis of 2CB-2OCD3 has been described.[1][2] 2CB-2OCD3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI).[1][2] It was patented in 2024[2] and was first described in the scientific literature in 2026.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues". Naunyn-Schmiedeberg's Archives of Pharmacology. June 2026. doi:10.1007/s00210-026-05566-5. PMID 42313138. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Daley PF, Cozzi NV, "Substituted phenylalkylamines", US patent 20240408038, published 2024-12-12, issued 2025-11-11, assigned to Alexander Shulgin Research Institute Inc